Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Eur Urol. 2016 Jun 9;70(6):985–992. doi: 10.1016/j.eururo.2016.05.023

Table 3.

Effect of treatment arm on multivariable models with and without CTC response in the COU-301 trial

Model without CTC responsea
Model with CTC responseb
HR (95% CI) p value HR (95% CI) p value
Week 4 0.65 (0.49–0.84) 0.001 0.87 (0.65–1.17) 0.352
Week 8 0.65 (0.49–0.86) 0.003 0.9 (0.66–1.24) 0.529
Week 12 0.73 (0.53–0.98) 0.041 0.86 (0.63–1.18) 0.360

CTC = circulating tumor cell; HR = hazard ratio for treatment arm (abiraterone vs placebo); CI = confidence interval.

a

Model includes: treatment arm; baseline CTC count (log-transformed); lactate dehydrogenase (log-transformed); albumin; alkaline phosphatase (log-transformed); hemoglobin; prostate-specific antigen (log-transformed); and Eastern Cooperative Oncology Group performance status.

b

Model includes: 30% CTC response at 4, 8, or 12 wk; treatment arm; baseline CTC count (log-transformed); lactate dehydrogenase (log-transformed); albumin; alkaline phosphatase (log-transformed); hemoglobin; prostate-specific antigen (log-transformed); and Eastern Cooperative Oncology Group performance status.